NASA/Methuselah Challenge Winners Make History by Engineering, Sustaining Live Human Tissue in a Laboratory
Achievement Breaks Scientific Logjam to Help Solve the Organ Shortage
News provided by
Share this article
Share this article
WASHINGTON, June 9, 2021 /PRNewswire/ Methuselah Foundation, which co-sponsored the Vascular Tissue Challenge with NASA, today announced the award-winning researchers achieved scientific breakthroughs that promise to dramatically change the future of human health.
The first- and second-place Challenge winners announced by NASA today are the first scientific teams to engineer and sustain thick functioning human tissue in a lab. The Challenge, first conceived by Methuselah Foundation in 2013, was conducted to increase the pace of bioengineering innovations to benefit humans on Earth and future space explorers.
2021 Honorees: NFL Alumni Health, the Klein Family), Feng Zhang, PhD and the Global Immunization Action Network Team (GIANT) and Joseph P. Vacanti, MD.
Data suggest that autologous administration of BM-MSCs in the treatment of T2DM should be performed in patients with T2DM duration <10 years and no obesity.
E-Mail
IMAGE: Research team from Vinmec Research Institute of Stem Cell and Gene Technology in Hanoi, Vietnam. view more
Credit: AlphaMed Press
Durham, NC Type 2 diabetes patients who are not overweight and who have had the disorder for less than a decade can benefit from stromal stem cells transplanted from their own bone marrow, according to a study published today in
STEM CELLS Translational Medicine.
In a randomized clinical trial at Vinmec Research Institute of Stem Cell and Gene Technology in Hanoi, Vietnam, researchers investigated the safety and potential therapeutic value of administering bone marrow stromal stem cells to patients with Type 2 diabetes. In each case, the cells were autologous, or taken from the patients own bodies.
Study: Some Type 2 diabetes patients can benefit from bone marrow stem cell transplants
Type 2 diabetes patients who are not overweight and who have had the disorder for less than a decade can benefit from stromal stem cells transplanted from their own bone marrow, according to a study published today in
STEM CELLS Translational Medicine.
In a randomized clinical trial at Vinmec Research Institute of Stem Cell and Gene Technology in Hanoi, Vietnam, researchers investigated the safety and potential therapeutic value of administering bone marrow stromal stem cells to patients with Type 2 diabetes. In each case, the cells were autologous, or taken from the patients own bodies.